The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a surge in biotech consolidation, AbbVie’s latest acquisition target is facing legal scrutiny over its valuation terms. Halper Sadeh LLC has launched an investigation into the fairness of the $135.11 per share cash offer presented by AbbVie to acquire Apogee Therapeutics. The probe aims to determine if Apogee’s board of directors fulfilled their fiduciary duties to shareholders and to identify potential violations of federal securities laws during the merger talks.
This investigation follows a pattern of heightened regulatory and legal oversight in the pharmaceutical sector, where AbbVie has been active, including its recent $10.1 billion acquisition of ImmunoGen according to Reuters reports. Compared to sector peers, the pricing of the Apogee deal is being closely analyzed to ensure it reflects the company's long-term pipeline value. Per market data, such legal challenges are common in multi-billion dollar mergers and rarely derail transactions unless significant fiduciary breaches are uncovered.
Sign in to access this content
Sign InMonitoring the stock performance, ABBV closed at $216.63 (as of June 18, 2026), having fluctuated between a high of $222.3 and a low of $215.37 during that session. Investors should watch for any legal filings that could delay the merger timeline, alongside upcoming US economic catalysts such as Building Permits and Housing Starts data, which may influence broader market volatility and healthcare sector positioning.